Cell Therapy and Long-Term Follow-Up
Novartis Pharma Services AG is involved in clinical research centered on patients previously treated with CAR T-cell therapy, with attention to extended monitoring after treatment across multiple indications.
- CAR T-cell therapy follow-up
- Post-treatment patient monitoring
- Delayed adverse effects
The research focus includes ongoing observation of individuals from different disease backgrounds who have received Novartis or Penn CAR T-cell treatment.
Safety Surveillance and Adverse Event Assessment
The sponsor’s trial portfolio emphasizes assessment of serious adverse events and other adverse events associated with prior cell therapy.
- Serious adverse events
- Adverse events related to prior therapy
- Delayed safety signals
This area reflects a strong interest in characterizing long-term tolerability after advanced cellular treatments.
Oncology-Related Cellular Therapy
Novartis maintains a therapeutic focus on oncology through research linked to CAR T-cell interventions used across different malignancies and disease settings.
- Hematologic malignancies
- Immune-based cancer therapy
- Cross-indication treatment follow-up
The studies involve patients from varied disease origins, supporting continued interest in the clinical course of cell-based cancer therapies.
Multicenter Clinical Research in Global Safety Monitoring
The sponsor’s research activity spans multiple active countries and collaborating sites, supporting broad clinical oversight for long-term outcomes after CAR T-cell therapy.
- International patient follow-up
- Multicenter safety evaluation
- Regulatory-guided monitoring
These studies are aligned with continued evaluation of late safety findings in patients treated with advanced cellular immunotherapy.
